• All
  • Article Title
  • Abstract
  • Keywords
  • Author
  • Institution
  • Citing Article List

    The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors”.
    No. Publication Date Citing Article
    1 2025 Anna Di Spirito, Sahar Balkhi, Veronica Vivona, Lorenzo Mortara. Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies, Exploration of Targeted Anti-tumor Therapy. 2025; 6: 1002304.  https://doi.org/10.37349/etat.2025.1002304
    2 2025 Vikrant Rai, Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives, Biomolecules. 2025; 15: 751.  https://doi.org/10.3390/biom15060751
    3 2023 Natasa Kustrimovic, Raffaella Bombelli, Denisa Baci, Lorenzo Mortara. Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment, International Journal of Molecular Sciences. 2023; 24: 1511.  https://doi.org/10.3390/ijms24021511
    4 2024 Margarita Zvirble, Zilvinas Survila, Paulius Bosas, Neringa Dobrovolskiene, Agata Mlynska, Gintaras Zaleskis, Jurgita Jursenaite, Dainius Characiejus, Vita Pasukoniene. Prognostic significance of soluble PD-L1 in prostate cancer, Frontiers in Immunology. 2024; 15: 1401097.  https://doi.org/10.3389/fimmu.2024.1401097
    5 2025 Akram Hoseinzadeh, Seyed-Alireza Esmaeili, Reza Sahebi, Anahita Madani Melak, Mahmoud Mahmoudi, Maliheh Hasannia, Rasoul Baharlou. Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights, Stem Cell Research & Therapy. 2025; 16: 33.  https://doi.org/10.1186/s13287-025-04158-z
    6 2025 Duo Zhang, Yu Heng, Qiu-yan Jin, Di Tang, Xiao-ke Zhu, Li-ming Lu, Chun-ping Wu, Lei Tao. Prognostic significance of cytotoxic-T-lymphocytes to immunosuppressive lymphocytes ratio (CIL) in laryngeal squamous cell carcinoma, Cancer Immunology, Immunotherapy. 2025; 74: 157.  https://doi.org/10.1007/s00262-025-04008-0
    7 2023 Feixiang Yang, Jiawei Li, Qintao Ge, Yuchen Zhang, Meng Zhang, Jun Zhou, Haitao Wang, Juan Du, Shenglin Gao, Chaozhao Liang, Jialin Meng. Non-coding RNAs: Emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer, Biochemical Pharmacology. 2023; 214: 115669115669.  https://doi.org/10.1016/j.bcp.2023.115669
    8 2025 Ngan Nguyen, Ian C. Henrich. Intra- and Extrahepatic Cholangiocarcinomas Display Differing Sensitivities to NK Cell Lysis and Modulate NK Cell Function through Shared and Distinct Pathways, Molecular Cancer Research. 2025; 23: 155.  https://doi.org/10.1158/1541-7786.MCR-24-0299
    9 2025 Whi-An Kwon, Jae Young Joung. Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers, Biomolecules. 2025; 15: 625.  https://doi.org/10.3390/biom15050625
    10 2025 Kadriia I. Enikeeva, Diana Kh. Gainullina, Polina N. Shmelkova, Yuliya V. Sharifyanova, Elina R. Akramova, Ildar R. Kabirov, Valentin N. Pavlov. Reprogramming the immune response in prostate cancer treatment, Urology reports (St. - Petersburg). 2025; 15: 75.  https://doi.org/10.17816/uroved646326
    11 2023 O. A. Korovin, A. V. Alyasova, Kh. M. Arioua, D. V. Novikov, N. V. Krasnogorova, V. V. Novikov. Analysis of the IL-10 mRNA level in the peripheral blood of patients with cancer and benign prostatic hyperplasia, Russian Journal of Biotherapy. 2023; 22: 35.  https://doi.org/10.17650/1726-9784-2023-22-4-35-42
    12 2024 Sandra C. Ordonez-Rubiano, Brayden P. Strohmier, Surbhi Sood, Emily C. Dykhuizen. SWI/SNF chromatin remodelers in prostate cancer progression, Frontiers in Epigenetics and Epigenomics. 2024; 1: 1337345.  https://doi.org/10.3389/freae.2023.1337345